ACR20 - Day 2 Report
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Industry Abstract Previews - ACR2020
Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020. This is our
ACR 2020 Your Way - Get Your Topic Emails
ACR is but a few days away; the question is: how will you tackle this virtual meeting?
RheumNow Podcast – Good Time Charlie…. (10.16.20)
Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.
RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
RheumNow Podcast – Function Follows Form (10.2.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)
Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.
RheumNow Podcast – Lupus Delights (9.18.20)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:
Mediterranean Diet May Reduce Risk of RA
Arthritis and Rheumatology reports that a Mediterranean diet (MD) is capable of reducing the high risk of RA among women who have smoked tobacco.
ACR 2020 Reproductive Guidelines - Lactation Guidance
The 2020 American College of Rheumatology (ACR) published guidelines on managing reproductive health issues in rheumatic disease (RMD) patients includes key guidance on preconception counseling, contraception, medication use and other unique scenarios.
ACR 2020 Reproductive Guidelines - Medication Use with Pregnancy
The American College of Rheumatology (ACR) has published guidelines to manage reproductive health issues in rheumatic disease (RMD) patients before, during and after pregnancy.
ACR 2020 Reproductive Guidelines - Contraception & Counseling
The American College of Rheumatology (ACR) established a guidelines committee that consisted of both patients, rheumatologists and maternal-fetal health experts.
Social
11.5% of Crohns pts have TNFi use contraindications (either MS, CHF, neoplasia, infx risk, TNFi AE, comorbidities, SLE. Alternatively GI survey respondents use ustekinumab (76%), vedolizumab (249%), or tofacitinib (0.5%) https://t.co/6ApUz93iS0 https://t.co/PTmnsTd2Wh
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 1 month ago
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/QUTIbK3r89 https://t.co/FZcTLREida
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 1 month ago
Rheumatologist Survey:
What do you rely on MOST in diagnosing Still’s disease?
Sxs? Labs? Both? Criteria? Fever?
Vote here:
https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 2 months ago
Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://t.co/uMY5uPPabA https://t.co/nG2RO6oEJQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 2 months ago
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Watch: Let’s Talk about Sex and Autoimmune Disease
Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022.
https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Deucravacitinib: TYK2 inhibitor in pts with active SLE
Phase 2, randomized, double blind, placebo-controlled study
Met primary endpoint SRI response across all doses
No death, MACE, VTE, systemic infections
@RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 3 months ago
@EricFMorand up first in late-breakings
PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid wean
Good outcomes:
primary: SRI(4) at 32w
skin/joint/LLDAS & dsDNA/C4
Safety good (like PsO/PsA) but higher dose less so
Watch for: other clinical, ph3
#EULAR2022 @RheumNow https://t.co/XOQWuiHkTx
David Liew @drdavidliew ( View Tweet )
3 years 3 months ago
Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD
Links:
Richard Conway @RichardPAConway ( View Tweet )
3 years 3 months ago
